P08.17 Mitotic checkpoint inhibition augments Tumor-Treating-Field (TTField) effects on glioblastoma cells

par Kessler, A. F.
Publié dans Neuro Oncol (2017)

P09.21 Complete radiological response after subtotal resection in two Gglioblastoma patients treated with Tumor Treating Fields

par Kessler, A. F., Linsenmann, T.
Publié dans Neuro Oncol (2017)

P14.59 Post-Market Surveillance Data of the EMEA region indicate good tolerability of TTFields in WHO Grade III Glioma

par Keßler, A F, Ritz, R
Publié dans Neuro Oncol (2019)

P06.06 Is activating transcription factor 5 (ATF5) a new therapeutic target in astrocytomas of different WHO grades and varying biological behavior? An expression analysis

par Feldheim, J. A., Keßler, A. F.
Publié dans Neuro Oncol (2016)

P08.20 Augmentation of Tumor-Treating-Field (TTField) effects on glioblastoma cells by mitotic checkpoint inhibition

par Frömbling, G. E., Kessler, A. F.
Publié dans Neuro Oncol (2016)

P14.60 FET PET response upon radiochemotherapy followed by Tumor Treating Fields (TTFields) in a patient with progressive high-grade glioma

par Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Publié dans Neuro Oncol (2019)

P14.28 First report on the combination of axitinib and Tumor Treating Fields (TTFields) in three patients with recurrent glioblastoma

par Keßler, A F, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M
Publié dans Neuro Oncol (2019)

O4.06 ANALYSIS OF RAF PROTEINS IN MALIGNANT GLIOMAS

par Hagemann, C., Gloger, J., Kessler, A.F., Linsenmann, T., Vince, G.H., Ernestus, R., Löhr, M.
Publié 2014

P04.33 Effects of Tumor Treating Fields (TTFields) on blood brain barrier (BBB) permeability

par Kessler, A F, Schaeffer, C, Burek, M, Ruschig, U, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Publié dans Neuro Oncol (2018)

P01.13 EXPRESSION OF HUMAN ENDOGENOUS RETROVIRUS K (HERV-K) IN HUMAN ASTROCYTIC TUMORS

par Kessler, A.F., Wiesner, M., Denner, J., Kämmerer, U., Löhr, M., Linsenmann, T., Vince, G.H., Ernestus, R., Hagemann, C.
Publié 2014

OS4.3 The BReMen trial: Patients with benign meningioma - is rehabilitation really necessary?

par Kessler, A F, Krause, K, Al-Shameri, B, Weiland, J, Linsenmann, T, Ernestus, R, Hagemann, C, Löhr, M, Jentschke, E
Publié dans Neuro Oncol (2018)

P11.28 Alteration of blood brain barrier (BBB) permeability by Tumor Treating Fields (TTFields) in vivo

par Keßler, A F, Salvador, E, Domröse, D, Burek, M, Tempel Brami, C, Voloshin Sela, T, Giladi, M, Ernestus, R, Löhr, M, Förster, C, Hagemann, C
Publié dans Neuro Oncol (2019)

P01.050 Circulating MACC1 transcript plasma levels in glioblastoma patients segregate together with prognostic markers and treatment response

par Hagemann, C, Neuhaus, N, Dahlmann, M, Kessler, A F, Kobelt, D, Herrmann, P, Eyrich, M, Freitag, B, Freitag, B, Linsenmann, T, Monoranu, C M, Ernestus, R, Löhr, M, Stein, U
Publié dans Neuro Oncol (2018)